Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres. MMD | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,212.434 |
Ending reported balance
After 2026-08-05 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-05 · Exercise / conversion · Acquired 6,311 · Balance 24,523.434 Row 2 · 2026-08-05 · Sale · Disposed 6,311 · Balance 18,212.434 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Row 3 · 2026-08-05 · Exercise / conversion · Acquired 9,709 · Balance 27,921.434 Row 4 · 2026-08-05 · Sale · Disposed 9,709 · Balance 18,212.434 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Row 5 · 2026-08-05 · Exercise / conversion · Acquired 2,686 · Balance 20,898.434 Row 6 · 2026-08-05 · Sale · Disposed 2,686 · Balance 18,212.434 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.73 · Expires 2031-05-03 | Direct | 3,154 |
Reported balance
After 2026-08-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-05 · Exercise / conversion · Disposed 6,311 · Balance 3,154 F2: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.10 · Expires 2032-05-02 | Direct | 0 |
Reported balance
After 2026-08-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-05 · Exercise / conversion · Disposed 9,709 · Balance 0 F3: The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.71 · Expires 2035-04-28 | Direct | 5,374 |
Reported balance
After 2026-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-05 · Exercise / conversion · Disposed 2,686 · Balance 5,374 F4: The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote.
F2: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.
F3: The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.
F4: The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,686 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 9 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,374 Underlying: Common Stock · 2,686 shares Expires 2035-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,709 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 8 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,709 shares Expires 2032-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,311 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 7 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,154 Underlying: Common Stock · 6,311 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 2,686 | $128.72 | $345,736.28 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 6 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,686 | $84.71 | $227,531.06 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 5 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,898.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,709 | $128.72 | $1,249,722.09 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 4 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,709 | $87.10 | $845,653.90 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 3 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,921.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,311 | $128.72 | $812,338.67 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 2 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,311 | $73.73 | $465,310.03 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 1 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,523.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,731 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000123 · form4.xml · derivative · entry 4 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,731 Underlying: Common Stock · 21,731 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 7,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000123 · form4.xml · derivative · entry 3 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,424 Underlying: Common Stock · 7,424 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 02, 2026 Filed May 5, 2026 17:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000113 · form4.xml · derivative · entry 3 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 552 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025, and 5/2/2026. Read SEC document |
| May 02, 2026 Filed May 5, 2026 17:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 159 | $112.16 | $17,833.44 |
DisclosureSEC source: 0000310158-26-000113 · form4.xml · nonDerivative · entry 2 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 Read SEC document |
| May 02, 2026 Filed May 5, 2026 17:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 552 | $112.16 | $61,912.32 |
DisclosureSEC source: 0000310158-26-000113 · form4.xml · nonDerivative · entry 1 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,371.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.